Scientific ReportsCancer BiologyPeer-reviewed journal article
A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation
A. Y. Ge, A. Arab, R. Dai, A. Navickas, L. Fish, K. Garcia, H. Asgharian, J. Goudreau, S. Lee, K. Keenan, M. B. Pappalardi, M. T. McCabe, L. Przybyla, H. Goodarzi, L. Gilbert
Abstract
The search for new approaches in cancer therapy requires a mechanistic understanding of cancer vulnerabilities and anti-cancer drug mechanisms of action. Problematically, some effective therapeutics target cancer vulnerabilities that have poorly defined mechanisms of anti-cancer activity. One such drug is decitabine, a frontline therapeutic approved for the treatment of high-risk acute myeloid leukemia (AML). Decitabine is thought to kill cancer cells selectively via inhibition of DNA methyltransferase enzymes, but the genes and mechanisms involved remain unclear. Here, we apply an integrated multiomics and CRISPR functional genomics approach to identify genes and processes associated with response to decitabine in AML cells. Our integrated multiomics approach reveals RNA dynamics are key regulators of DNA hypomethylation induced cell death. Specifically, regulation of RNA decapping, splicing and RNA methylation emerge as important regulators of cellular response to decitabine.
- organism: human
- assay: bulk RNA-seq
- assay: DNA methylation
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of chromatin-based determinants of azacytidine and decitabine anti-cancer activity
Rishi V. Puram, Qiangzong Yin, … Todd R. Golub·bioRxiv·Jul 29, 2025
- Dissection of demethylation and toxicity induced gene expression changes after decitabine treatment.
Andrey A. Turchinovich, Harald Surowy, … Barbara Burwinkel·bioRxiv·Dec 18, 2019
- DNA methylation protects cancer cells against senescence
Xiaoying Chen, Kosuke Yamaguchi, … Pierre‐Antoine Defossez·Nature CommunicationsPeer-reviewed·Jul 1, 2025
- Targeted systematic evolution of an RNA platform neutralizing DNMT1 function and controlling DNA methylation
Carla Lucia Esposito, Ida Autiero, … Annalisa Di Ruscio·Nature CommunicationsPeer-reviewed·Jan 6, 2023
- The type of DNA damage response after Decitabine treatment depends on the level of DNMT activity
T. Aumer, L. Bergmayr, … F. R. Traube·bioRxiv·Sep 2, 2023
- DNMT inhibitors increase methylation of CpGs related to p53 pathway genes in colon, lymphoma, bladder, ovarian, and breast cancer cells
A. K. Giri, T. Aittokallio·bioRxiv·Sep 8, 2018